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There are several reports in the litera-
ture which claim superiority of primidone 
over phenobarbitone and phenytoin in 
the treatment of major epilepsy, (Nathan, 
1954; Butter, 1953 and Oxley et al., 
1980). It has also been the impression 
of some workers that primidone is effective 
in controlling refractory cases either when 
given alone or in combination with phe-
nytoin (Butter, 1953; Grant, 1971; and 
Goodman and Gillman, 1980). On the 
other hand Gruber et al. (1962) did not 
find primidone superior to phenobarbitone 
and other anticonvulsants. However, it 
is still believed that primidone is a more 
potent antiepileptic and may even be of 
help in refractory cases. Despite extensive 
clinical experience the drug at least in our 
country is still not used as a first line of 
treatment. 
The present study therefore was desig-
ned to re-evaluate the efficacy of pri-
midone as a first line treatment of epilepsy 
and reassess its value in refractory cases. 
METHODOLOGY: 
54 consecutive cases of major epilepsy 
comprising of grandmal, psychomotor and 
complex partial seizures were taken up for 
the study from the psychiatric Clinic of 
L. L. R. Hospital, Kanpur. Of the 54 
cases who were started on primidone 4 
patients dropped out without completing 
the trial and two had complaints of drow-
siness and dizziness, severe enough to dis-
continue the medication. Of the 48 
patients, 26 had either never received any 
treatment or had discontinued treatment 
atleast 6 months prior to the commence-
ment of primidone therapy. These were 
grouped as 'fresh cases'. The remaining 
22 were termed as 'refractory cases' in 
whom the reduction in fit frequency by 
the adequate doses of previous anti-epilep-
tic therapy was less than 50%. 
Patients thus selected, were subjected 
to detailed clinical history, physical exami-
nation and a thorough neurological check 
up along with routine blood examination 
and urine analysis. Wherever necessary, 
X-rays of skull and E. E. G. were also 
done to arrive at a proper diagnosis. The 
patients received primidone in a range 
varying from 500 mg to 1500 mgs per day 
in divided doses. As one of the most 
common side effects of primidone is drow-
siness the patients were started on a smaller 
dose. Fresh cases were given one-fourth 
of the 250 mg tablet at bed time initially 
while refractory cases were started on 125 
mg at bed time. The doses were gradua-
lly increased every third day reaching the 
maximum level of 1000 to 1500 mg during 
a period 7 to 14 days. The patients 
were also properly warned of this side 
effect as to discourage them from discon-
tinuing the medication on their own. 
The refractory cases were switched over to 
primidone after gradually discontinuing 
the previous medication and enhancing 
primidone. Only those are included in 
the study who have completed the trial 
period of one year. 
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OBSERVATIONS 
Out of 48 cases there were 34 men 
and 14 women, the age ranged from 7 to 60 
years with a mean age of 32.5 years. 34 
patients had typical grandmal epilepsy, 
8 had psychomotor fits and 6 presented 
with complex partial seizures. Patients 
with complex partial seizures had been 
on some or the other anticonvulsants and 
belonged to the category of refractory 
cases. The mean duration of illness in 
fresh and refractory cases was 4.6 years 
and 7.2 years respectively. 
The effectiveness of the drug was 
mainly evaluated on the basis of reduction 
in the fit frequencies. The response was 
categorised as 'good' when the reduction 
in the fit frequency was 75% or more, sa-
tisfactory when the decrease in the number 
of fits was between 50% and 75%, while 
response was considered poor if reduction 
in the fit frequencies was less than 50%. 
There was a significant reduction in 
the fit frequencies of the fresh cases after 
primidone therapy (table I). More than 
60% fresh patients remained seizure free 
during the one year trial period. 
TABLE 1. Primidone in fresh cases (N=26) 
Before pri- After Pri-
midone midone 
Therapy Therapy 
N % N % 
Fit frequencies 
More than once in a month 6 23.1 2 7.7 
Once in 1 to 3 months 12 46.1 3 11.5 
Once in 3 to 6 months 4 15.4 2 7.7 
Onct in 6 month to 1 yrs. 4 15.4 3 11.5 
Nil .... 16 61.3 
Level of significance p <.01 
The anticonvulsant drugs which the 
refractory cases have been taking are shown 
in table 2. The fits became significantly 
less frequent in refractory cases as well 
after primidone therapy (table 3). 50% 
TABLE 2. Previous aniiepileptic therapy in 
refractory eases (^"=22) 
Drugs Number Percentage 
Phenytoin 5 22.7 
Phenobarbitone 7 31.8 
Carbamaiepine 3 13.6 
Phenytoin+Phenobarbitone 7 31.8 
TABLE 3.  Primidone in refractory cases (JV=s 
22). 
Before Pri- After Pre-
midone midone 
Therpy Therapy 
N % N % 
Fit frequencies 
More than once in a mcnth 
Once in 1 to 3 months 
Once in 3 in to 6 months 
Once in 6 month to 1 year 
Nil 
4 
8 
7 
3 
— 
18.2 
36.4 
31.8 
13.6 
— 
1 
4 
3 
2 
12 
4.5 
18.2 
13.6 
9.1 
54.6 
Level of significance p < .01 
TABLE 4. Global response to primidone in 
fresh and refractory cases 
Good Satisfactory Poor 
N % N % N % 
Fresh cases (N =26) 19 73.1 3 11.5 4 15.4 
Refractory cases 
(N=22) 14 63.6 2 9.1 6 27.3 
Level of significance—N. S. 
patients never had any fit during the 
trial period. It is further seen in table 
4 that primidone is equally effective in 
fresh as well as refractory cases. 73% of 
the fresh and 67% refractory case have 
shown good response. The commonly PRIMIDONE IN EPILEPSY  225 
TABLE 5. Side effects of primidone 
Side effects Fresh cases Refractory 
cases 
(N=26) (N=22) 
N % N % 
Drowsiness 14 63.8 8 36.3 
Dizziness 9 34.6 6 27.3 
Gastrointestinal upset 2 7.7 1 4.5 
observed side effects were drowsiness and 
dizziness (table 5) which however, were less 
frequent in refractory cases. 
DISCUSSION 
Primidone, though an established anti-
convulsant for over 30 years has mainly 
been used in our country as second line 
treatment of epilepsy. The present study 
was an attempt to reassess the value of 
primidone both in fresh as well as refrac-
tory cases. The results of our study as 
well as those of Livingstone and Peterson 
(1956), Timberlake et al. (1955) and 
Whitty (1953) who have also used primi-
done in fresh cases, found the drug to be 
a highly effective anticonvulsant in cont-
rolling major fits such as grandmal, psy-
chomotor and complex partial seizures. 
Intolerable drowsiness is seen in only two 
cases. 
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